When are combination approaches -- with a DMARD and biologic -- used to treat RA and when might monotherapeutic approaches be preferable?

When are combination approaches -- with a DMARD and biologic -- used to treat RA and when might monotherapeutic approaches be preferable?

When are combination approaches — with a DMARD and biologic — used to treat RA and when might monotherapeutic approaches be preferable?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ernest Choy, MD, FRCP

Ernest Choy, MD, FRCP

Head of Rheumatology and Translational Research
Institute of Infection and Immunity
Director of Arthritis Research UK CREATE Centre and
Welsh Arthritis Research Network (WARN) Cardiff University School of Medicine
Cardiff, United Kingdom